Loss of MeCP2 function is associated with distinct gene expression changes in the striatum

Area of Science:

• Neuroscience
• Genetics
• Molecular Biology

Background:

• Rett syndrome (RTT) is a neurodevelopmental disorder linked to mutations in the methyl-CpG binding protein 2 (MeCP2) gene.
• MeCP2 regulates gene transcription, and its loss-of-function causes RTT-like phenotypes in mice.
• The specific role of MeCP2 in the striatum, crucial for motor control and cognition, remained largely uncharacterized.

Purpose of the Study:

• To investigate the gene expression changes in the striatum of MeCP2-deficient mice.
• To determine if MeCP2 loss affects gene expression in a tissue- or cell-type specific manner.

Main Methods:

• Characterization of gene expression in the striatum of constitutive Mecp2-null mice and mice with MeCP2 deletion in forebrain GABAergic neurons.
• Analysis of differentially expressed genes in striatum, hypothalamus, and cerebellum.
• Bioinformatic analysis of gene expression data.
• Examination of gene expression in the liver of Mecp2-null mice.

Main Results:

• Significant differentially expressed genes were identified in the striatum of MeCP2-mutant mice, particularly when RTT-like symptoms manifested.
• Many striatal gene expression changes were novel and not observed in the hypothalamus or cerebellum.
• Loss of MeCP2 did not globally alter gene expression landscapes across studied brain regions.
• Differentially expressed genes were also found in the liver, indicating a role for MeCP2 in non-neuronal tissues.

Conclusions:

• MeCP2 plays a critical role in maintaining proper brain function, with its loss leading to specific molecular alterations in the striatum.
• MeCP2 function and the resulting gene expression changes are tissue- and cell-type specific.
• Understanding MeCP2's function requires a cellular context, highlighting its diverse roles beyond neuronal tissues.